Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ivana Gojo

Showing results (41-50 of 122) with videos related to

Pageof 13
Sort By:
Annals of Clinical and Laboratory Science|October 29, 2005
Histone deacetylase inhibitor pharmacodynamic analysis by multiparameter flow cytometryEun Joo Chung, Sunmin Lee, Edward A Sausville, et al.
Leukemia & Lymphoma|July 21, 2021
A phase II study of azacitidine in combination with granulocyte-macrophage colony-stimulating factor as maintenance treatment, after allogeneic blood or marrow transplantation in patients with poor-risk acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS)Jonathan A Webster, Meera Yogarajah, Marianna Zahurak, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 17, 2008
Phase II trial of tipifarnib as maintenance therapy in first complete remission in adults with acute myelogenous leukemia and poor-risk featuresJudith E Karp, B Douglas Smith, Ivana Gojo, et al.
Cancer Chemotherapy and Pharmacology|November 21, 2018
Population pharmacokinetics and exposure-response assessment of veliparib co-administered with temozolomide in patients with myeloid leukemiasRenu Singh, Shailly Mehrotra, Mathangi Gopalakrishnan, et al.
Neurology|April 3, 2013
Pearls and oy-sters: the utility of cytology and flow cytometry in the diagnosis of leptomeningeal leukemiaDaniel R Gold, Robyn E Nadel, Christina G Vangelakos, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 21, 2010
Single cycle of arsenic trioxide-based consolidation chemotherapy spares anthracycline exposure in the primary management of acute promyelocytic leukemiaSteven D Gore, Ivana Gojo, Mikkael A Sekeres, et al.
JCI Insight|November 3, 2018
Signatures of CD8+ T cell dysfunction in AML patients and their reversibility with response to chemotherapyHanna A Knaus, Sofia Berglund, Hubert Hackl, et al.
Blood Advances|September 8, 2018
Immune checkpoint inhibitors as a bridge to allogeneic transplantation with posttransplant cyclophosphamideLaura K Schoch, Kenneth R Cooke, Nina D Wagner-Johnston, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 14, 2013
Translational phase I trial of vorinostat (suberoylanilide hydroxamic acid) combined with cytarabine and etoposide in patients with relapsed, refractory, or high-risk acute myeloid leukemiaIvana Gojo, Ming Tan, Hong-Bin Fang, et al.
British Journal of Haematology|July 22, 2014
A phase 1 clinical trial of vorinostat in combination with decitabine in patients with acute myeloid leukaemia or myelodysplastic syndromeMark Kirschbaum, Ivana Gojo, Stuart L Goldberg, et al.
Pageof 13

Showing results (41-50 of 122) with videos related to

Sort By:
Pageof 13
Annals of Clinical and Laboratory Science|October 29, 2005
Histone deacetylase inhibitor pharmacodynamic analysis by multiparameter flow cytometryEun Joo Chung, Sunmin Lee, Edward A Sausville, et al.
Leukemia & Lymphoma|July 21, 2021
A phase II study of azacitidine in combination with granulocyte-macrophage colony-stimulating factor as maintenance treatment, after allogeneic blood or marrow transplantation in patients with poor-risk acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS)Jonathan A Webster, Meera Yogarajah, Marianna Zahurak, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 17, 2008
Phase II trial of tipifarnib as maintenance therapy in first complete remission in adults with acute myelogenous leukemia and poor-risk featuresJudith E Karp, B Douglas Smith, Ivana Gojo, et al.
Cancer Chemotherapy and Pharmacology|November 21, 2018
Population pharmacokinetics and exposure-response assessment of veliparib co-administered with temozolomide in patients with myeloid leukemiasRenu Singh, Shailly Mehrotra, Mathangi Gopalakrishnan, et al.
Neurology|April 3, 2013
Pearls and oy-sters: the utility of cytology and flow cytometry in the diagnosis of leptomeningeal leukemiaDaniel R Gold, Robyn E Nadel, Christina G Vangelakos, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 21, 2010
Single cycle of arsenic trioxide-based consolidation chemotherapy spares anthracycline exposure in the primary management of acute promyelocytic leukemiaSteven D Gore, Ivana Gojo, Mikkael A Sekeres, et al.
JCI Insight|November 3, 2018
Signatures of CD8+ T cell dysfunction in AML patients and their reversibility with response to chemotherapyHanna A Knaus, Sofia Berglund, Hubert Hackl, et al.
Blood Advances|September 8, 2018
Immune checkpoint inhibitors as a bridge to allogeneic transplantation with posttransplant cyclophosphamideLaura K Schoch, Kenneth R Cooke, Nina D Wagner-Johnston, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 14, 2013
Translational phase I trial of vorinostat (suberoylanilide hydroxamic acid) combined with cytarabine and etoposide in patients with relapsed, refractory, or high-risk acute myeloid leukemiaIvana Gojo, Ming Tan, Hong-Bin Fang, et al.
British Journal of Haematology|July 22, 2014
A phase 1 clinical trial of vorinostat in combination with decitabine in patients with acute myeloid leukaemia or myelodysplastic syndromeMark Kirschbaum, Ivana Gojo, Stuart L Goldberg, et al.
Pageof 13